Which statin is preferred for an adult with chronic kidney disease and severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m², not on dialysis)?

Preferred Statin in Severe Renal Impairment (eGFR <30 mL/min/1.73 m²)

For adults with severe renal impairment (eGFR <30 mL/min/1.73 m²) not on dialysis, atorvastatin or pravastatin are the preferred statins, as they require no dose adjustment and have the best safety profile in this population.

Specific Statin Recommendations by Renal Function

First-Line Choices for eGFR <30 mL/min/1.73 m²:

Atorvastatin is the optimal choice because 1:

• No dosage adjustment needed at any level of kidney function
• Extensively studied in CKD populations
• Provides moderate-to-high intensity lipid lowering as recommended by guidelines

Pravastatin is an excellent alternative 1:

• No dosage adjustment required
• Not metabolized by cytochrome P450 3A4, reducing drug interaction risk 2
• Lower risk of myopathy in renal impairment

Statins Requiring Dose Adjustment (Use with Caution):

Rosuvastatin 1:

• When eGFR <30 mL/min/1.73 m², initiate at 5 mg daily
• Do not exceed 10 mg daily
• Requires close monitoring

Simvastatin 1:

• Initiate at 5 mg daily in severe kidney disease
• Higher risk of drug interactions via CYP3A4 metabolism 3
• Used in SHARP trial (with ezetimibe) but requires careful dosing

Lovastatin 1:

• Use cautiously when creatinine clearance <30 mL/min
• Doses >20 mg daily should be avoided

Statins to Avoid:

Fluvastatin 1:

• Not studied at doses >40 mg in severe kidney disease
• Use with extreme caution

Clinical Context and Guidelines

The 2019 AHA/ACC guidelines recommend moderate-intensity statins (or moderate-intensity statin plus ezetimibe) for adults with CKD not on dialysis 4. The KDIGO 2015 commentary specifically notes that atorvastatin and pravastatin prescribing information indicates no dose adjustment is needed even in severe renal impairment 5.

The 2022 ADA/KDIGO consensus reinforces that a statin is recommended for all patients with CKD 6, with moderate intensity for primary prevention and high intensity for those with established ASCVD.

Key Safety Considerations

Drug Interaction Risk:

• Avoid statins metabolized by CYP3A4 (simvastatin, lovastatin, atorvastatin to lesser extent) when patients are on macrolide antibiotics, calcium channel blockers, or amiodarone 3
• Pravastatin and fluvastatin have the lowest interaction risk as they bypass CYP3A4 2

Monitoring Requirements:

• Check creatine kinase if symptoms of myopathy develop
• The risk of rhabdomyolysis increases with declining renal function 3
• Atorvastatin and pravastatin have demonstrated the best safety profiles in severe CKD 1

Evidence for Benefit in Severe CKD

The SHARP trial demonstrated that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events in patients with mean eGFR 27 mL/min/1.73 m² 5, 4. This supports statin use even in advanced CKD not requiring dialysis. Recent meta-analyses confirm statins reduce mortality and cardiovascular events in stage 3-4 CKD 7, 8.

Important caveat: Do not initiate statins in patients already on dialysis 4, though continuing existing therapy may be reasonable 4.

Practical Algorithm

1. eGFR <30 mL/min/1.73 m², not on dialysis: Start atorvastatin 10-20 mg daily OR pravastatin 10-40 mg daily
2. If drug interactions are a concern: Choose pravastatin (no CYP3A4 metabolism)
3. If rosuvastatin is preferred: Start 5 mg daily, maximum 10 mg daily
4. Avoid: High-dose simvastatin, lovastatin >20 mg, fluvastatin >40 mg
5. Monitor: Symptoms of myopathy, not routine lipid levels 9